Blueprint Medicines

This #NationalInternDay, we're celebrating the contributions of this year's intern cohort and their meaningful impact across our organization. We believe in supporting young talent through inclusive early career programs that bring fresh perspectives into our company and the life sciences industry. Join Erin Lopez, our Human Resources Intern, as she shares a day in her life as a summer intern in our Cambridge office.

Our responsibility to help patients goes beyond delivering innovative treatments. Through personalized patient support and extensive education programs, we strive to understand the holistic experience of living with SM and tailor the assistance we provide to meet patients' diverse needs, enabling them to navigate their health with knowledge and confidence.

Jennifer has turned the vulnerability she’s experienced from living with systemic #mastocytosis (SM) into her superpower. Michele, an artist who helped Jennifer express her experience through art, is inspired by her enduring love of life and willingness to face constant challenges in her desire to be free. At our inaugural Colors of SM event on Friday, we unveiled the artwork they created together in an exhibit featuring pieces from 6 individual pairings. In collaboration with Twist Out Cancer, the Colors of SM program aims to bring to life the real-world impacts of SM, increasing compassion and understanding. For more information, visit the #ColorsOfSM website: https://lnkd.in/e5KdnJDq

We’ve wrapped up an inspiring weekend at The Mast Cell Disease Society, Inc.’s #MastCellCon. This event hosted patients, caregivers, advocates, HCPs and more in person and online to discuss latest research, innovation and education in mast cell diseases. We’re deeply committed to supporting people living with systemic mastocytosis, increasing understanding of the disease and raising awareness of patients’ experiences. Check out our #BlueCrew at the event and read more from Fatima Scipione, VP of Global Patient Affairs, below: https://shorturl.at/tAnAu

Creating a shared understanding of the real-world impacts of systemic mastocytosis (SM) is crucial to support and empower those living with the disease. Today, we're unveiling an inaugural art exhibit from our 'Colors of SM: Expressions of Life with Systemic Mastocytosis' program, which illuminates the experiences of people living with SM through the transformative power of creative arts. In collaboration with Twist Out Cancer, Colors of SM pairs talented artists with individuals living with SM to create a unique work of art that reflects their personal journey with the disease. #ColorsOfSM Read more: https://bit.ly/3W4bDIa

We aim to meaningfully impact patients’ lives by actively understanding their perspectives and acting upon what we learn. We’re proud to support The Mast Cell Disease Society, Inc.’s #MastCellCon this weekend in Indianapolis, where we'll hear directly from the mast cell community about their experiences, hopes and aspirations for the future. If you’re attending, come and find the #BlueCrew at the event!

This week, our offices worldwide will be closed for our annual Global Summer Well-Being Shutdown. We take our people-first approach seriously and recognize the importance of nurturing a healthy work-life balance. This is the first of two week-long shutdowns we offer each year to provide time to recharge and rest. Thank you to the #BlueCrew for your relentless drive and unwavering commitment to patients throughout the year. For now, we're out of office, so we'll see you next week!

Since our founding, we've worked closely with patient communities to ensure our programs incorporate real-world insights and positively impact the patients we serve. From early development through commercialization, we dedicate time to engaging with patients to hear their perspectives, collaborating with patient advocacy groups, creating educational programs, and more. At Blueprint Medicines, patients are our priority as we strive to improve and extend people's lives globally.

After more than a decade studying systemic mastocytosis (SM), we've built a deep understanding of mast cells and their role in driving several allergic/inflammatory diseases. We also recognize the KIT receptor as a key regulator of mast cell activation, proliferation, and survival.   Using our innovative scientific platform that drives continued discovery of novel therapies, along with our proven ability to inhibit the KIT D816V mutation in SM, we aim to apply our knowledge to other mast cell-driven diseases. Learn how below:

"He promised me that if I came to Blueprint, I'd find a warm and welcoming environment that would help me develop a skillset in clinical development." Mentors, advisors and support networks serve as an essential part of shaping one's career path. Listen in as Benjamin Lampson, Medical Director, and Javier I. Muñoz Gonzalez, Ph.D., Director of Clinical Development, recount their journeys to Blueprint Medicines and places they've found supportive environments for professional growth. We're proud that our talented #BlueCrew is comprised of people across multiple disciplines, united by our goal to advance innovative therapies that improve and extend patients' lives.